Population Pharmacokinetics and Exposure‐Response Analyses for the Most Frequent Adverse Events Following Treatment With Lemborexant, an Orexin Receptor Antagonist, in Subjects With Insomnia Disorder

Lemborexant is a novel orexin receptor antagonist approved in the United States and Japan for the treatment of insomnia. This article describes the population pharmacokinetics (PK) of lemborexant and the relationship of its daily steady‐state exposure (C(av,ss)) to the probability of most frequent t...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:J Clin Pharmacol
Hoofdauteurs: Lalovic, Bojan, Majid, Oneeb, Aluri, Jagadeesh, Landry, Ishani, Moline, Margaret, Hussein, Ziad
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: John Wiley and Sons Inc. 2020
Onderwerpen:
Pharmacometrics
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7689791/
https://ncbi.nlm.nih.gov/pubmed/32666570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/jcph.1683
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items